The short version of modified GRF(1-29) fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-07 and is reviewed periodically as new material appears.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
FGI of 6-Chloro-2-tetralone [17556-18-2] (1) to its enamine by reaction with pyrrolidine (or with the chiral amine 1-phenethylamine to ensure enantioselectivity) gives 1-(6-chloro-3,4-dihydronaphthalen-2-yl)pyrrolidine [54670-11-0] (2). Reaction with acrylamide [79-06-1] would be expected to be a 2-phase process. First a conjugate Michael addition occurs followed by displacement of pyrrolidine by the amide nitrogen to form an unsaturated lactam. The product of this step is called 8-chloro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one, PC10466539 (3). The lactam-olefin at the ring junction is reduced with triethylsilane in the presence of trifluoroacetic acid. The saturated lactam consists largely of racemic isomer with the trans ring junction. Alkylation of the lactam nitrogen with methyl halide in the presence of base gives 8-Chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one [152323-03-0] (4). Treatment with methanol opens the lactam ring to yield the corresponding methyl ester, PC10826711 (5). The amino-ester is next resolved via its ditoluyl tartrate salt giving PC10516975 (6). Finally, heating with sodium carbonate regenerates the lactam ring to afford Bexlosteride (7). N.B. The starting tetralone finds dual use in the synthesis of 6-CAT.
=== Connective tissue disorders === Marfan's Syndrome is a connective tissue disorder that can lead to chronic aortic or mitral regurgitation. Osteogenesis imperfecta is a disorder in formation of type I collagen and can also lead to chronic aortic regurgitation.
== Fifth Ministry == On 16 December 1977, following the 1977 election on 12 November, the Ministry was reconstituted. Due to the death of Keith Hooper on 23 August 1977, there was a vacancy in the outgoing ministry, to which Charles Porter was appointed. A number of minor changes occurred:
In 1865 the German chemist Adolf von Baeyer began working on the synthesis of indigo. He described his first synthesis of indigo in 1878 (from isatin) and a second synthesis in 1880 (from 2-nitrobenzaldehyde). (It was not until 1883 that Baeyer finally determined the structure of indigo.) The synthesis of indigo remained impractical, so the search for alternative starting materials at Badische Anilin- und Soda-Fabrik (BASF) and Hoechst continued. In 1890, Dr Flimm of Darmstadt, Germany, discovered a simple method for synthesizing indigo with a derivative of acetanilide using caustic potash. This reaction produced a blue compound chemically identical to natural indigo that was identified by its reactions and absorption spectrum. This publication of independent dye synthesis experiments in scientific journals during this period demonstrates that the production of synthetic indigo was a widely pursued goal in industrial chemistry well before BASF's successful market launch. By 1897, BASF had developed an economically viable synthesizing process that replaced natural plant production. Earlier attempts to replace plant-based production were ineffective on an industrial scale. Johannes Pfleger and Karl Heumann eventually came up with industrial mass production synthesis. The synthesis of N-(2-carboxyphenyl)glycine from the easy to obtain aniline provided a new and economically attractive route. BASF developed a commercially feasible manufacturing process that was in use by 1897, at which time 19,000 tons of indigo were being produced from plant sources.
== Decreased GFR == A decreased renal function can be caused by many types of kidney disease. Upon presentation of decreased renal function, it is recommended to perform a history and physical examination, as well as performing a renal ultrasound and a urinalysis. The most relevant items in the history are medications, edema, nocturia, gross hematuria, family history of kidney disease, diabetes and polyuria. The most important items in a physical examination are signs of vasculitis, lupus erythematosus, diabetes, endocarditis and hypertension. A urinalysis is helpful even when not showing any pathology, as this finding suggests an extrarenal etiology. Proteinuria and/or urinary sediment usually indicates the presence of glomerular disease. Hematuria may be caused by glomerular disease or by a disease along the urinary tract. The most relevant assessments in a renal ultrasound are renal sizes, echogenicity and any signs of hydronephrosis. Renal enlargement usually indicates diabetic nephropathy, focal segmental glomerular sclerosis or myeloma. Renal atrophy suggests longstanding chronic renal disease.
Sources: en.wikipedia.org
=== World War I === In 1916, BASF started operations at a new site in Leuna, where explosives were produced during the First World War. On 21 September 1921, an explosion occurred in Oppau, killing 565 people. The Oppau explosion was the biggest industrial accident in German history.
GSHS (disambiguation) ГШ (disambiguation) (Russian: GSh) All pages with titles containing GSH or GSHs All pages with titles containing g-s-h All pages with titles beginning with GSH All pages with titles beginning with Gsh All pages with titles beginning with G.S.H. GS (disambiguation)
Activation: Ubiquitin is activated in a two-step reaction by an E1 ubiquitin-activating enzyme, which is dependent on ATP. The initial step involves production of a ubiquitin-adenylate intermediate. The E1 binds both ATP and ubiquitin and catalyses the acyl-adenylation of the C-terminus of the ubiquitin molecule. The second step transfers ubiquitin to an active site cysteine residue, with release of AMP. This step results in a thioester linkage between the C-terminal carboxyl group of ubiquitin and the E1 cysteine sulfhydryl group. The human genome contains two genes that produce enzymes capable of activating ubiquitin: UBA1 and UBA6. Conjugation: E2 ubiquitin-conjugating enzymes catalyse the transfer of ubiquitin from E1 to the active site cysteine of the E2 via a trans(thio)esterification reaction. In order to perform this reaction, the E2 binds to both activated ubiquitin and the E1 enzyme. Humans possess 35 different E2 enzymes, whereas other eukaryotic organisms have between 16 and 35. They are characterised by their highly conserved structure, known as the ubiquitin-conjugating catalytic (UBC) fold. Ligation: E3 ubiquitin ligases catalyse the final step of the ubiquitylation cascade. Most commonly, they create an isopeptide bond between a lysine of the target protein and the C-terminal glycine of ubiquitin. In general, this step requires the activity of one of the hundreds of E3s. E3 enzymes function as the substrate recognition modules of the system and are capable of interaction with both E2 and substrate. Some E3 enzymes also activate the E2 enzymes.
The Jourdan Road warehouse was built in 2003 and has 160,000 square feet (4,500,000 cubic feet) of refrigerated cold storage warehouse with a total storage capacity of 46,000,000 lbs of product. It features 24 truck bays and three vessel berths and maintains USDA export certification, approval from the Russian confederation for poultry exports, and approval for poultry and beef exports to Mexico. It is especially designed to blast freeze meat and poultry to 0 degrees Fahrenheit within 24 hours with a total capacity of 1,200,000 lbs a day.
In 2023, world production of black peppercorns was 855,105 tonnes, led by Vietnam with 30% of the total, and Brazil, Indonesia, and India as secondary producers. Peppercorns are among the most widely traded spices in the world, accounting for 20% of all spice imports.
Sources: en.wikipedia.org
== Bibliography == Lui, G.; Bruenger, F.W.; Barrios, A. M.; Miller, S.C. (1995). "Synthesis of 2-Alkyl-3-Hydroxy-4-Pyridinone-Ribonucleosides, Potential Oral Iron Chelators". Nucleosides and Nucleotides. 14: 1901–1904. Barrios, A.M. and Lippard, S.J. (2000). "Interaction of Urea with a Hydroxide-Bridged Dinuclear Nickel Center: An Alternative Model for the Mechanism of Urease". J. Am. Chem. Soc.. 122(38): 9172–9177. Barrios, A.M. and Craik, C.S. (2002). "Scanning the Prime-Site Substrate Specificity of Proteolytic Enzymes: A Novel Assay Based on Ligand-Enhanced Lanthanide Ion Fluorescence". Bioorg. Med. Chem. Lett.. 12: 3619–3623. Stanford, S.M.; Panchal, R.G.; Walker, L.M.; Falk, M.D.; Mitra, S.; Damle, S.S.; Ruble, D.; Kaltcheva, T.; Zhang, S.; Zhang, Z.-Y.; Bavari, S.; Barrios, A.M.; Bottini, N. (2012). "High-Throughput Screen Using a Single-Cell Tyrosine Phosphatase Assay Reveals Biologically Active CD45 Inhibitors". Proc. Natl. Acad. Sci.. 109(35): 13972–13977. Barrios, A. and Mitra, S. (July 2, 2015). "Coumarin-based amino acids for use in enzyme activity and substrate specificity assays". United States Patent and Trademark Office. Bottini, N.; Stanford. S.; Barrios, A.; Mitra, S. (March 19, 2013). "Method for monitoring intracellular tyrosine phosphatase activity". United States Patent and Trademark Office. Debnath, A.; Parsonage, D.; Andrade, R.; He, C.; Cobo, E.; Hirata, K.; Chen, S.; Garcia-Rivera, G.; Orozco, E.; Martinez, M.; Gunatilleke, S.; Barrios, A.M.; Arkin, M.; Poole, L.; McKerrow, J.; Reed, S. (2012).
During this period Wigler's lab published the first use of epitope tagging for protein purification. Following the success with epitope tagging, Wigler and collaborator Joe Sorge patented methods for the creating libraries of genes encoding diverse families of antibody molecules. The concept of antibody libraries is most often combined with the method of phage display used in development of antibody-based therapeutics. In the early 1990s, Wigler and collaborator W. Clark Still at Columbia University developed the first method for encoding combinatorial chemical synthesis, a method for using gas chromatography tags to record reaction "history" while building vast libraries of chemical compounds. This approach is still used today for drug discovery. In this same period, Wigler and Nikolai Lisitsyn developed the concept and applications of representational difference analysis, which led to their identification of new cancer genes, including the tumor suppressor PTEN, and by others the cancer virus-causing Kaposi's sarcoma, KSHV. In the late '90s, Drs. Wigler and Robert Lucito combined genome representations with array hybridization leading to a technique called ROMA used to show common structural variation in genomes. In the decade since 2004, Wigler and Jim Hicks at CSHL, together with Anders Zetterberg of the Karolinska Institute, applied methods of copy number analysis for prognostication of breast cancer. The need for accurate measurement of nucleic acid molecules led to the development of varietal tags, more commonly known as unique molecular identifiers.
While Seaborg applied for funding, Harvey worked on the einsteinium target, while Thomson and Choppin focused on methods for chemical isolation. Choppin suggested using α-hydroxyisobutyric acid to separate the mendelevium atoms from those of the lighter actinides. The initial separation was done by a recoil technique suggested by Albert Ghiorso: the einsteinium was placed on the opposite side of the target from the beam, so that the momentum of the recoiling mendelevium atoms would allow them to leave the target and be caught on a gold catcher foil behind it. This recoil target was made by an electroplating technique, developed by Alfred Chetham-Strode. This technique gave a very high yield, which was absolutely necessary when working with such a rare and valuable product as the einsteinium target material. The recoil target consisted of 109 atoms of 253Es which were deposited electrolytically on a thin gold foil. It was bombarded by 41 MeV alpha particles in the Berkeley cyclotron with a very high beam density of 6×1013 particles per second over an area of 0.05 cm2. The target was cooled by water or liquid helium, and the foil could be replaced. Initial experiments were carried out in September 1954. No alpha decay was seen from mendelevium atoms; thus, Ghiorso suggested that the mendelevium had all decayed by electron capture to fermium-256, correctly believed to decay primarily by fission, and that the experiment should be repeated, this time searching for those spontaneous fission events. This version of the experiment was performed in February 1955.
For services to People with Dementia and their Families. Dr. Emma Lucy Wilson. Director of Technical, Production and Costume, Royal Opera House. For services to the Performing Arts. William Wilson. Senior Officer, National Crime Agency. For services to Law Enforcement. Belinda Ann Winstone. Team Leader, Army Bereavement and Aftercare Services. For services to Military Families. Joan Harris Winterkorn. Archive and Manuscript Consultant and Member, Acceptance in Lieu Panel, Arts Council England. For services to Heritage and Culture. Theresa Wise. Chief Executive, Royal Television Society. For services to Broadcasting. Nicola Clare Wood. Senior Independent Director, Information Commissioner's Office. For services to Regulation. Mary Elizabeth Woods. Lately Nurse Consultant, The Royal Marsden NHS Foundation Trust. For services to Lymphoedema. Caroline Valerie Wright. Early Childhood Director, Bright Horizons Nursery. For services to Early Years Education. Judith Kathleen Wright. Trustee, Orders of St John Care Trust and lately Chair, St John Priory Group for Buckinghamshire. For voluntary service to the Order of St John. Stephen Richard Wright. Broadcaster. For services to Radio. Gloria Ingrid Wyse. Head of Research and Content, Business in the Community. For services to Diversity and Inclusion. Dr. Richard Kenneth Howard Wyse. Director of Clinical Development, Cure Parkinson's. For services to Medicine in Parkinson's Disease. Susan Yates. Officer, National Crime Agency. For services to Law Enforcement. Allan Reid Young. Head of Instrumental Music, Perth and Kinross.
Standard peptides synthesized from amino acids labeled with stable isotope atoms serve as internal standards for serial dilutions of a sample. These allow for later absolute quantification of proteins and post-translational modifications by mass spectrometry. This technique has been adapted to absolute quantification of proteases, deciphering both activity states and total amounts in biological samples. This is thanks to trypsin treatment for mass spectrometry generating peptides specific to inactive zymogen precursors, active proteases, or common to both forms. PSPs is one form of standard peptide for absolute quantification and Standard of the Expressed Protease (STEP) is the other. The major difference between the two is PSP sequences are designed to mimic tryptic peptides that contain sequences spanning the zymogen's pro-domain and the protease's final form, whereas STEP sequences match tryptic peptide sequences found in both forms of the protease. This capitalizes on protease activation, where the zymogen's pro-domain is cleaved off and the final form lacks that domain. Experiments using iTRAQ labeling and LC-MS/MS with STEP and PSP peptide internal standards have successfully quantified total and active protease levels in biological samples. One major drawback for this approach is the inability to account for inhibitor bound enzymes. It is also difficult to ensure standard peptides can be generated for this method for each and every protease for study.
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.